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Abstract
Introduction
Iron deficiency is a treatable cause of severe anaemia in low-and-middle-income-countries
(LMIC). Diagnosing it remains challenging as peripheral blood markers poorly reflect bone-
marrow iron deficiency (BM-ID), especially in the context of HIV-infection.
Methods
Severely anaemic (haemoglobin�70g/l) HIV-infected adults were recruited at Queen Eliza-
beth Central Hospital, Blantyre, Malawi. BM-ID was evaluated. Accuracy of blood markers
(including hepcidin, mean corpuscular volume, mean cellular haemoglobin concentration,
serum iron, serum ferritin, soluble transferrin receptor (sTfR), sTfR index, sTfR–ratio) to
detect BM-ID was evaluated by ROC area under the curve (AUCROC).
Results
Seventy-three patients were enrolled and 35 (48.0%) had BM-ID. Although hepcidin and
MCV performed best (AUCROC of 0.593 and 0.545 respectively) all markers performed
poorly in identifying BM-ID (ROC<0.6). The AUCROC of hepcidin in males was 0.767 (sensi-
tivity 80%, specificity 78%) and in women 0.490 (sensitivity 60%, specificity 61%).
Conclusion
BM-ID deficiency was common in severely anaemic HIV-infected patients. It is an important
and potential treatable contributor to severe anaemia but lack of definitive biomarkers
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makes it difficult to accurately assess iron status in these patients. Further investigation of
the potential of hepcidin is needed, including exploration of the differences in hepcidin
results between males and females.
Introduction
Anaemia affects approximately a third of the world’s population and substantially reduces
the disability- adjusted life years worldwide [1]. Iron deficiency contributes to develop-
ment of anaemia and is diagnosed in more than half of all anaemic persons [2]. Conse-
quently, iron supplements remain the backbone of prevention and treatment protocols for
anaemia.
Anaemia has an extensive list of potential causes. In sub-Saharan Africa, where this condi-
tion is most common, its aetiology is even more complex and its investigation requires a multi-
factorial approach [3, 4]. HIV may cause anaemia by its direct effect on BM cells, but can also
affect other aetiological factors including opportunistic viral, bacterial and parasitic infections,
drugs such as zidovudine and co-trimoxazole, micronutrient deficiencies and neoplastic dis-
eases [5, 6]. The exact role of iron deficiency, as one of the few preventable and treatable causes
of anaemia, remains unclear due to its diagnostic challenges in HIV-infected patients in low
resource settings [3, 4, 7]. However iron supplementation has been shown to be a risk factor
for infections in areas of high infectious burden [8, 9]. Peripheral blood markers for iron defi-
ciency, including erythrocyte indices, serum iron, ferritin, and soluble transferrin receptor
(sTfR), have been evaluated but their accuracy is often negatively affected by inflammatory
states, and renal and liver conditions, which are common in both the African and HIV-
infected populations [10–13]. Previous studies therefore concluded that peripheral blood
markers of iron status, such as ferritin, might not be reliable without a correction for inflam-
mation [14, 15].
The evaluation of iron in the bone marrow is considered the ‘gold standard’ to diagnose
iron deficiency, but bone marrow sampling is invasive and requires skilled staff for sampling
and interpretation, which is challenging in low resource settings. Moreover, for large-scale use,
a reliable peripheral blood marker to predict bone marrow iron deficiency (BM-ID) is needed
to replace bone-marrow biopsy.
Hepcidin is a relatively new marker, which regulates iron absorption from the gastrointesti-
nal tract and iron release from stores, both of which are important pathways controlling the
availability of iron for incorporation in the erythrocyte precursors [16]. Increases of iron
plasma levels stimulate the production of hepcidin, which blocks further iron absorption from
the gastrointestinal tract and release of stored iron. In situations where erythropoietin demand
and/or hypoxia are present (as in severe anaemia), hepcidin levels are decreased [17–19]. How-
ever, hepcidin is also upregulated by inflammation which may limit its use in settings where
infections are common [20]. Hepcidin may have potential to guide iron therapy in severely
anaemic children because in this population there is diminished up regulation of hepcidin in
inflammation and iron deficiency due to an increase in erythropoietin [17]. It is therefore
important to explore the possible role of hepcidin as a useful marker in guiding iron therapy in
severely anaemic adults.
We investigated the prevalence of BM-ID in HIV-infected Malawian adult patients with
severe anaemia. We further evaluated the accuracy of peripheral blood markers, as well of hep-
cidin to identify BM-ID in this population.
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Methods
From February 2010 to March 2011, all adults admitted to the Department of Internal Medi-
cine of the Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi with a diagnosis of
severe anaemia and HIV infection were approached for informed consent and study enrol-
ment. This study was a sub-study of a larger observational cohort study (n = 199) of severely
anaemic (haemoglobin� 70 g/l) HIV-infected patients. Bone marrow sampling was per-
formed if the patient consented and was clinically stable. This sub-study comprises 73 (37%) of
the patients in the main study since for these patients BM samples of adequate quality were
available.
Laboratory assays and blood markers
Haemoglobin concentration was measured on admission using the HemoCue B-Haemoglobin
analyser (HemoCue, A¨ngelholm, Sweden) to screen patients for eligibility. After informed
consent a venous blood sample was collected and bone marrow sample taken from the iliac
crest. All blood samples were analysed within 24 hours of collection or stored at -80˚C. Hae-
moglobin and red cell indices (MCV, MCH and MCHC) were determined using an automated
haematology analyser (Beckman Coulter, Durban, South Africa). CD4-cell counts were
assessed using BD FACS Count (BD Biosciences, San Jose, CA, USA). Transferrin, iron, ferri-
tin, folate and vitamin B12 were analysed on Modular P800 and Monular Analytic E170 sys-
tems (Roche Diagnostics, Switzerland). Soluble transferrin receptor (sTfR) levels were
measured using ELISA (Ramco Laboratories, TX, USA). Commonly used ratios to define iron
deficiency were calculated including the sTfR index: sTfR (mg/L) divided by log ferritin (ug/
L); and the ‘sTfR ratio’: sTfR (mg/L) x1000/ ferritin (ug/L) level [21]. International accepted
cut-offs were applied. No international cut-offs have been defined for sTFR or for the sTFR
index so we tested several previously used cut-offs. For sTfR we used 2.7 mg/l, 3.6 mg/l and 8.3
mg/l and for the sTfR index 1.8, 2.2 and 2.8 repectively [21–23].
Serum hepcidin-25 measurements were performed between December 2012 and January
2013 (Testing lab: Hepcidinanalysis.com, Nijmegen, The Netherlands) by a combination of
weak cation exchange chromatography and time-of-flight mass spectrometry (WCX-TOF MS)
using synthetic hepcidin-24 as internal standard [24–26]. Peptide spectra were generated on a
Microflex LT matrix-enhanced laser desorption/ionisation TOF MS platform (Bruker Dal-
tonics, Bremen, Germany). Hepcidin concentrations are expressed as nanogram per millilitre
(ng/ml). The lower limit of detection of this method was 0.5 ng/ml [25].
BM-ID
Bone marrow aspirate samples were spread onto slides and trephine biopsies were fixed, decal-
cified and embedded in paraffin wax [27, 28]. Bone marrow samples were sent to the Haema-
tology Pathology Referral Centre at the Royal Liverpool University Hospital, Liverpool UK, for
analysis. Sections of the trephine blocks were stained with Perls’ Prussian Blue to detect iron
stores [28]. Intracellular iron in bone marrow trephine blocks was graded using the Stuart-
Smith scale, which classifies the iron content of bone marrow into six grades (0–6). For bone
marrow smears, iron was graded using Gale’s grading (0–4). Iron deficiency was defined as no
visible or severely reduced iron particles in reticulum cells under high power magnification;
grade 0–1 on both scales [29, 30]. The reviewing pathologist was only provided with the
patient’s identification number and was not aware of the clinical condition of the patient when
reviewing the bone marrow.
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Infections
HIV infection was confirmed using two point-of-care antibody tests (Unigold1 and Deter-
mine1). Different types and severity of on-going and potential infections were evaluated
including; HIV: CD4 counts�200 cells/mm3 and/or viral load>1000 copies/ml. Malaria:
presence of malaria parasites in a thick blood film assessed by light microscopy. Tuberculosis
(TB) defined as one or more of the following: a) positive sputum culture; b) chest X-ray with
signs of pulmonary tuberculosis and/or; c) on-going TB treatment at time of enrolment; d)
clinical diagnosis based on generalized lymphadenopathy and/or night sweats > 30 days with
unknown origin; e) caseating granulomata in the bone marrow trephine. Bacteraemia was
defined as a blood culture that grew a potential pathogen including streptococcus, enterococ-
cus and micrococcus species, non-Typhoid Salmonella and Klebsiella pneumonia. Viral infec-
tions including parvo-B19, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were
evaluated by PCR and defined as positive by viral load>100 copies/ml.
Ethics
The Research Ethics Committee of the College of Medicine, University of Malawi
(P.09.09.824) and the Research Ethics Committee of Liverpool School of Tropical Medicine
(research protocol 09.64) approved the study. The purpose of the study was explained to the
patients in the local language (Chichewa), and written informed consent was obtained before
inclusion into the study.
Statistics
The data were analysed using Stata (version 12) (STATA Corp. LP, Texas, TX, USA). Baseline
characteristics were compared between BM-ID and non-iron-deficient patients using Chi-
square test (dichotomous data) or t-test (continuous) or Pearson Chi-square test (continuous
not normally distributed). To assess any confounding factors, hepcidin concentrations were
evaluated by gender, HIV disease progression, the use of ART at enrolment, and TB infection
(Pearson Chi-square test). The p-values reported are two-sided, and a level of p<0.05 was
interpreted as significant. The accuracy of the different peripheral blood markers, including
hepcidin, to discriminate BM-ID was evaluated by receiver operating characteristics curves
(ROC)[31]. Corresponding areas under the curve (AUCROC) were created. AUCROC measures
the two-dimensional area underneath the ROC curve and provides a summative measure of
performance across all possible classification thresholds [32]. The AUCROC <0.70 is consid-
ered to be of low diagnostic accuracy; AUCROC of 0.70–0.90 as moderately accurate and a
AUCROC�0.90, of high diagnostic accuracy [33]. Sensitivity and specificity were calculated for
predefined internationally accepted cut-offs [10, 21, 23, 34]. For hepcidin the best cut-off value
for diagnosing BM-ID was determined using ROC-curve analyses with the Youden index
(maximum (sensitivity + specificity– 1))[32]. As gender differences are known to occur for
hepcidin [30], hepcidin results were disaggregated by gender.
Results
Of the 73 HIV-infected adults in this study, a total of 45 (61.6%) had severe anaemia (Hb 50-
<70g/dL) and 28 (38.4%) had very severe anaemia (Hb<50g/dL). The mean patient age was
33.7 (SD 8.7) years, and 43 (58.9%) patients were female. A CD4 count� 200 cells/mm3 was
present in 31/56 (55.4%) and a viral load>1000 copies/ml was present in 57/76 (75.0%) of
patients. A total of 34/73 (46.6%) patients were on anti-retroviral ART treatment at enrolment,
of which most were on first line treatment at time of the study (Efavirenz, Lamivudine,
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Tenofovir). The most common infections in this population were tuberculosis (39/73; 53.4%)
and EBV (30/45; 66.7%). All baseline characteristics are shown in Table 1.
BMI-ID and blood markers
BM-ID was seen among 35 (48.0%) of the patients (Table 1). The performances of the periph-
eral blood markers to diagnose BM-ID are displayed in Table 2. All markers displayed low
diagnostic accuracy (AUCROC< 0.7). MCV had the highest AUCROC value of the common
peripheral blood markers (0.545), the sensitivity and specificity using the common cut off of
Table 1. Baseline characteristics in this population of severely anaemic HIV patients, stratified according to bone marrow iron deficiency (BM-ID).
Characteristic Overall Non BM-ID BM-ID
BM-ID 35/73 (48.0%) 38/73 (52.1%) 35/73 (48.0%)
Age, years (mean, SD) 33.7 (8.7) 32.7 (8.6) 34.7 (8.9)
Gender (female) (%) 43/73 (58.9%) 19/38 (50.0%) 24/35 (68.6%)
Haematology and iron markers
Very severe anaemia (Hb� 50g/l) (%) 28/73 (38.4%) 13/38 (34.2%) 15/35 (42.9%)
Haemoglobin(Hb)(g/l)(median, IQR) 56.0 (43.0–63.0) 58.5 (45.0–64.0) 54.0 (36.0–63.0)
MCV (fl) (median, IQR) 85.8 (79.4–98.1) 87.3 (79.6–99.0) 83.5 (79.1–94.7)
MCH (pg/cells) (mean, SD) 29.0 (5.9) 23.6 (6.1) 26.3 (5.5)
Serum iron (umol/l) (median, IQR) 5.1 (3.3–11.1) 4.7 (3.0–7.9) 5.6 (3.8–22.2)
Ferritin (ug/dL) (median, IQR) 87.2(49.6–100.0) 87.1 (50.1–97.1) 87.9(36.0–100.0)
sTfR receptor (mg/l) (median, IQR) 2.9(1.6–3.7) 2.8(1.7–3.7) 3.0(1.2–3.9)
sTfR index (median, IQR) 1.6 (0.8–2.2) 1.5 (0.9–2.1) 1.6 (0.6–2.6)
sTfR Ratio (median, IQR) 35.1 (17.5–69.3) 33.2 (21.3–61.9) 36.6(11.5–79.6)
Hepcidin (ng/ml) (median, IQR) 7.3(3.3–13.3) 9.2 (4.9–13.2) 5.1 (3.1–13.7)
HIV disease and treatment
ART at enrolment (%) 34/73 (46.6%) 20/38 (52.6%) 14/35 (40.0%)
CD4 count� 200 cells/mm3 31/56 (55.4%) 15/28 (53.6%) 14/25(56.0%)
Viral load >1000 copies/ml 57/76 (75.0%) 25/38 (65.8%) 30/35 (85.7%)
Infection(s)
Bacteraemia 3 12/73 (16.4%) 6/38 (15.8%) 6/35 (17.1%)
Malaria4 3/63 (4.7%) 2/32 (6.3%) 1/31 (3.2%)
Tuberculosis5 39/73 (53.4%) 20/38 (52.6%) 19/35 (54.3%)
Epstein-Barr virus 6 30/45 (66.7%) 19/26 (73.1%) 11/19 (57.9%)
Cytomegalovirus 6 18/54 (33.3%) 11/28 (39.3%) 7/26 (26.9%)
Parvo-B19 virus6 1/59 (1.7%) 0/27 (-) 1/32 (3.1%)
Nutritional status
Underweight (BMI < 18.5) (%) 22/49 (44.9%) 8/24 (33.3%) 14/25 (56.0%)
All tested p-values were > 0.1. Abbreviations: ART: antiretroviral therapy. BMI: Body mass index. TB: Tuberculosis.
1 First line ART include combination of Stavudine (d4T), Lamivudine (3Tc) and Nevirapine (NVP) [35].
2 Advanced HIV disease including a CD4 count� 200 cells/mm3 and/or viral load > 1000 copies/ml.
3Bacteraemia; a blood culture with a potential pathogen including streptococcus (41.7%; 5/12), enterococcus (16.7%;2/12) and non-Typhoid Salmonella (16.7%;2/12).
4Malaria: presence of malaria parasites on a thick blood film.
5Tuberculosis (TB): one or more of the following present: a) positive sputum culture, b) chest X-ray with signs of pulmonary tuberculosis and/or c) on-going TB
treatment at time of enrolment d) clinical diagnosis by local doctor including unknown generalized lymphadenopathy and/or night sweats > 30 days with unknown
origin e) caseating granulomata in the bone marrow trephine.
6 Epstein-Barr, cytomegalo- and parvo-B19 virus infection are diagnosed by a viral load of 1000 copies/ml. Abbreviations: MCV; mean cellular volume, MCH; mean
corpuscular haemoglobin, s-TfR: Soluble transferrin receptor, TfR-index (sTfR(mg/L) /Log ferritin(ug/L)), TfR Ratio (sTrR(mg/L))x1000/ferritin(ug/L)).
https://doi.org/10.1371/journal.pone.0218694.t001
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83fL were 42% and 67% respectively. The use of hepcidin to detect BM-ID resulted in an
AUCROC 0.593. We stratified the analysis for hepcidin according to gender; the AUCROC for
men and women was 0.767 and 0.490 respectively. The optimal hepcidin concentration for the
detection of BM-ID was�7 ng/ml (sensitivity 67%, specificity 67%). In males the optimum
cut off was�6 ng/ml (sensitivity 80%; specificity 78%) whilst for women this was�7 ng/ml
(sensitivity 60%; specificity 61%, Fig 1). The hepcidin concentration did not differ significantly
by gender (p = 0.831), HIV disease progression (p = 0.819), the use of ART at enrolment
(p = 0.616), and TB infection (p = 0.590) in a univariate analysis. Hepcidin levels were nega-
tively correlated with sTfR receptor (mg/l)3; Beta -0.62, p = 0.041) and positive towards sTfR
index (sTfR(mg/L) /Log ferritin(ug/L)); Beta 8.3, p-value 0.001), S1 Table.
Discussion
In this study on hepcidin and conventional markers to detect BM-ID in severely anaemic
HIV-infected patients in Malawi, we found that BM-ID was present in almost half of our
patients. In this study, the first evaluating hepcidin as a marker for BM-ID among severely
anaemic HIV-infected adults in this setting, we found all tested markers performed subopti-
mally in detecting BM-ID. Hepcidin was the best performing marker but had a suboptimal
accuracy (AUCROC 0.593), which was less pronounced in males (AUCROC 0.767). Hepcidin
and (standardized) identified cut-offs may therefore have some use as a marker to define
BM-ID and to guide iron supplementation in HIV-infected patients in resource limited set-
tings such as Malawi. Intervention studies, using hepcidin as a marker in males and females,
should be performed to assess feasibility and effect of such a test.
BM-ID was highly prevalent among our population of HIV-infected and severely anaemic
patients. It was higher than in previous reports on similar populations that were published in
Table 2. Accuracy of peripheral blood markers to detect bone marrow iron deficiency (gold standard).
Potential markers AUCROC 95%-CI Cut-off Sensitivity 95%-CI Specificity 95%-CI
MCV (fl)1 0.545 0.404–0.685 �83 42% 25.2–58.8% 67% 51.0–83.0%
MCH (pg/cells) 1 0.365 0.230–0.499 �27 52% 35.2–69.0% 29% 13.7–44.3%
Serum iron (μmol/l) 1 0.368 0.239–0.498 � 10 60% 43.8–76.2% 18% 5.8–30.2%
Ferritin (μg/l) 1 0.441 0.293–0.588 �30 13% 1.0–25.0% 88% 76.7–99.3%
�70 30% 13.6–46.4% 66% 49.6–82.4%
sTfR receptor (mg/l)3 0.522 0.378–0.667 �2.7 58% 40.6–73.1% 56% 39.3–72.7%
�3.6 32% 15.6–48.2% 76% 61.6–99.4%
�8.3 3% 0–9.0% 100% 100%
sTfR index 4 0.523 0.375–0.672 �1.8 47% 29.1–64.9% 67% 46.3–79.7%
�2.2 27% 11.1–42.9% 75% 60.0–90.0%
�2.8 20% 5.7–34.3% 81% 67.4–94.6%
sTfR Ratio 4 0.508 0.359–0.656 �100 17% 0–23.4% 91% 71.1–90.9%
Hepcidin5 overall 0.593 0.447–0.739 7.0 67% 50.2–83.8 67% 51.6–82.4
Hepcidin5 Males 0.767 0.567–0.960 6.0 80% 55.2–100.0 78% 52.9–91.1
Hepcidin5 Females 0.490 0.298–0.682 7.0 60% 38.5–81.5 61% 38.5–83.5
Abbreviations: AUC: area under curve of receiver operating characteristic (ROC), where 0.5 would be expected by chance and 1 denotes a test with perfect diagnostic
accuracy. 95%-CI: 95% confidence interval. MCV; mean cellular volume, MCH; mean corpuscular haemoglobin, sTfR: Soluble transferrin receptor, sTfR index (sTfR
(mg/L) /Log ferritin(ug/L)), sTfR Ratio (sTrR(mg/L))x1000/ferritin(ug/L)).
1 [29] 2 [11] 3 [22] 4[21, 23]. 4 Hepcidin results are shown based on outcome of Fig 1. The best cut-off value for diagnosing BM-ID was determined by the Youden index
(maximum (sensitivity + specificity −1)) in the ROC-curve [32].
https://doi.org/10.1371/journal.pone.0218694.t002
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the pre-ART era when BM-ID was reported to be 18%-25% in severely anaemic HIV patients
[10, 36]. The high prevalence of BM-ID in our patients may be explained by the effect of ART.
Previous reports on HIV-associated anaemia before 2010 included patients who were mostly
ART naïve, and advanced HIV disease and/or severe immune suppression were common [10].
Although VL above 1000 copies/ml (75%) and CD4 counts below 200 cells/ml were (55.4%)
still common in our study population, median CD4 counts (325 cells/mm3) were much higher
than in the previous reports (median 67 cells/ml) [4, 10]. Initiation of ART aims to stop HIV
disease progression, promote immune reconstitution and reduce the risk of (opportunistic)
diseases. These effects may be reflected in our cohort, and have likely changed the aetiology of
severe anaemia among HIV-infected patients compared to older, pre-ART studies. In our
group of HIV-infected patients, who probably have less immunosuppression, the aetiology of
severely anaemic may be more similar to the aetiology in non-HIV infected patients. The
BM-ID prevalence of 48% is comparable to previous findings among HIV-uninfected African
populations with severe anaemia, which supports this hypothesis [10]. Our data need to be
confirmed in the on-going ‘treat all’ ART era but they have potential to impact on preventive
and curative policies concerning iron supplementation in severely anaemic HIV-infected
patients. Irrespective of the cause, the role of iron supplementation to prevent and treat severe
anaemia appears to have gained importance.
Our results concerning the accuracy of peripheral blood markers to detect BM iron defi-
ciency indicate that it is not easy to reliably detect those with deficient BM iron stores, which
corroborates previous studies [10, 11]. Hepcidin did perform slightly better than conventional
markers, but was still sub-optimal especially in females. Additionally, hepcidin is a key player
in the absorption of iron and thus may be used to not only identify patients needing iron but
also may predict iron supplementation, response, safety and timing. Hepcidin as a possible
marker for BM-ID has not been evaluated before in this population of severely anaemic HIV-
infected adults in Africa. It is not surprising that hepcidin is not an optimal marker for BM-ID
as hepcidin levels are affected by inflammation which is common among HIV-infected
patients, especially those living in resource-limited settings [37–39]. For example, when hepci-
din levels are high, the absorption of dietary iron and release of macrophage iron to serum are
Fig 1. Hepcidin (ng/ml) ROC curve by gender with optimal cut-off. The best cut-off value for diagnosing BM-ID, Table 1, was determined by the Youden
index (maximum (sensitivity + specificity −1)) in the ROC-curve (32). Hepcidin overall; AUCROC 0.593, optimal cut-off�7 ng/ml (sensitivity 67% and
specificity 67%). Hepcidin in males; AUCROC 0.767 optimal cut-off�6 ng/ml (sensitivity 80%; specificity 78%). Hepcidin in females 0.490 optimal cut-off�7
ng/ml (sensitivity 60% and specificity 61%. Abbreviations: AUCROC: area under curve of receiver operating characteristic.
https://doi.org/10.1371/journal.pone.0218694.g001
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blocked, resulting in a relative hypoferremia and an increase in iron in the macrophages; this
is thought to be a protection mechanism against infections. Consequently during malaria or
TB infection, or immune deficiency with low CD4 counts, hepcidin levels are increased [38,
39]. Among children in Malawi, including children with HIV, we have previously reported
low hepcidin levels [17]. As low hepcidin levels are likely to be due to diminished up-regula-
tion of hepcidin in response to inflammation and iron deficiency (due to an increase of eryth-
ropoietin) in this population, hepcidin was suggested as a possible useful marker in guiding
iron therapy [17]. However, low hepcidin levels during severe anaemia is not exclusive for an
absence of inflammation other potential involvement of hepcidin suppressive signals during
severe anaemia, as for example an ineffective erythropoiesis should also be considered.
Worldwide hepcidin concentrations are measured by various methods, which differ consid-
erably in absolute hepcidin concentrations [40]. Recently, secondary hepcidin reference mate-
rial, that has been value-assigned by a primary reference material, has become available [41].
Standardization in February 2019 of a similar hepcidin assay to the one we used in 2012–13,
resulted in only a 5.4% increase of hepcidin concentrations (C. Laarakker and D. Swinkels
unpublished data) [42]. For our study population, our results provide a first and rough esti-
mate for hepcidin cut-off points that are comparable to other assays that have been standard-
ized using the reference material. However, for formal universal use of these cut-off points
these values should be confirmed by studies that directly measure samples with a standardized
hepcidin method. Additionally, hepcidin optimal cut-offs were more sensitive and lower for
men compared to women and age and gender differences in hepcidin concentrations are
known. For the age group of our study population (mean 30–35 years) normal hepcidin con-
centrations have been reported to be higher in men than women [41, 43]. However this refer-
ence data is based on European populations: hepcidin reference levels are not known for
African populations. These age, sex and potential geographical differences make any direct
comparisons challenging. Our results therefore need to be confirmed with studies that use the
recently standardized hepcidin method.
Iron deficiency is treatable and preventable, however supplementation has been associated
with an increased number of severe infections, including malaria, which, especially in an
immune compromised population, may be dangerous [9, 44]. Moreover recently (2019) it has
been shown that iron supplementation in a HIV population is related to increased mortality
[45]. Therefore a reliable diagnosis of iron deficiency in HIV-infected patients is important, as
supplementation could put the patients at risk. Our study underlined that the currently used
peripheral blood markers for iron deficiency performed poorly. This is a common problem
especially in resource limiting settings where poor performance has been related to inflamma-
tory conditions which are particularly frequent African HIV-infected patients [10, 11]. Some
of the markers tested, such as sTfR concentrations, alone or in combination with other mark-
ers, may better reflect iron stores [46] irrespective of inflammation [47]. Although sTfR had a
poor AUCROC it did have a better sensitivity than hepcidin and thus may be used to screen for
iron deficiency. Overall sTfR levels in our population were low compared to other studies [48].
This may reflect the high prevalence of inflammation and end-stage HIV disease in our popu-
lation, which are both associated with low sTfR levels [38]. The method we used for sTfR was
feasible in the Malawian setting but other studies have used different methods for sTFR so our
results may not be directly comparable to results from other studies. We have therefore evalu-
ated several previously published cut-offs for sTFR and used AUC-ROC curves to try and
identify potential improved cut-offs. Reasons for the poor performances of sTfR in our popula-
tion may be the lack of clear cut-offs, as suggested by other studies [10], and the fact that sTfR
is also influenced by erythropoietin, which may play an important role in severe HIV-associ-
ated anaemia [38]. The best, though still suboptimal, conventional peripheral blood marker for
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iron deficiency, was MCV. Microcytosis is commonly used as a screening test for iron defi-
ciency [34, 49,50]; however, MCV has not been found to be an accurate predictor of BM-ID
[10, 11, 48]. Our findings confirm this as MCV did not have a high sensitivity or specificity
and the AUCROC was of low diagnostic value.
Our study has several shortcomings. Firstly, bone marrow testing was only performed in a
subset of patients, which may have introduced a sampling bias. Reasons for not taking bone
marrow included a severe clinical condition of the patient, or patients not consenting to this
aspect of the study. However, it is one of the largest studies of one marrow iron deficiency in
African HIV-infected patients to date. Secondly, our study was performed in 2010 when ART
was provided according to the national and hospital guidelines. Accordingly, ART could only
be started in the outpatient ART clinic after discharge from hospital. Currently ART is started
much earlier in the course of HIV infection so our study patients are likely to have had more
advanced HIV disease than current patients. Other than screening for pathogens, we did not
determine inflammatory markers such as CRP in our patients. Nevertheless, this is the first
study combining bone marrow data with a large set of peripheral blood markers, including
hepcidin, in a group of HIV-infected severely anaemic African patients. Hepcidin may be
influenced by multiple interacting stimuli in this patient population including, iron deficiency,
anaemia, hypoxia and inflammation. We found an inverse association between hepcidin and
sTfR, which may indicate that inflammation was an important factor in our population. Low
hepcidin values in our patients indicate that iron stores are deficient and suggest that iron sup-
plements will likely be absorbed. However, the effectiveness and safety should be evaluated in
a prospective trial design in this population. We believe our study provides valuable informa-
tion for clinicians who care for HIV-infected patients with severe anaemia in Malawi and
other resource-limited settings.
Conclusion
Bone marrow iron deficiency was present in almost half of severely anaemic HIV-infected
adults. This is higher than comparative data from the pre-ART era, and underlines the poten-
tial importance of preventive and therapeutic iron supplementation to reduce the problem of
severe anaemia in HIV-infected patients. Detection and safe treatment of BM-ID is hampered
by a lack of informative markers of iron deficiency. Although suboptimal, and not routinely
available in resource-poor settings, hepcidin was found to be the most accurate marker of
those we evaluated, and may be helpful to guide and predict the effect of iron supplementation.
Precise knowledge of an individual’s iron status is important because of the potential risk of
increased infection risk due to iron supplementation, so the effectiveness of using hepcidin
should be evaluated in future intervention studies.
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